The latest price target for Maze Therapeutics (NASDAQ:MAZE) was reported by Truist Securities on April 14, 2026. The analyst firm set a price target for $64.00 expecting MAZE to rise to within 12 months (a possible 121.68% upside). 21 analyst firms have reported ratings in the last year.

The latest analyst rating for Maze Therapeutics (NASDAQ:MAZE) was provided by Truist Securities, and Maze Therapeutics maintained their buy rating.

There is no last upgrade for Maze Therapeutics

There is no last downgrade for Maze Therapeutics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Maze Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Maze Therapeutics was filed on April 14, 2026 so you should expect the next rating to be made available sometime around April 14, 2027.

While ratings are subjective and will change, the latest Maze Therapeutics (MAZE) rating was a maintained with a price target of $68.00 to $64.00. The current price Maze Therapeutics (MAZE) is trading at is $28.87, which is out of the analyst’s predicted range.